Chimeric Therapeutics Limited
ASX: CHM.AX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Australian Securities Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Rebecca McQualter
- Headquarters
- Carlton, Australia
- IPO year
- 2021
- Market cap
- A$6.1M
- Website
- https://www.chimerictherapeutics.com
Loading CHM…
Loading profile data…Frequently asked questions about CHM
What does Chimeric Therapeutics Limited (CHM.AX) do?
Chimeric Therapeutics Limited, a clinical stage cell therapy company, develops and commercializes a range of cell therapies in oncology in Australia. The company develops CHM 0201 (core NK platform) that is in phase I clinical trial for treating solid tumors and hematological malignancies; and CHM 1101 (CLTX CAR T), which is in phase I clinical...
Where does CHM.AX trade?
Chimeric Therapeutics Limited (CHM.AX) trades on the Australian Securities Exchange.
What sector is CHM.AX in?
Chimeric Therapeutics Limited (CHM.AX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Chimeric Therapeutics Limited?
Rebecca McQualter is the chief executive officer of Chimeric Therapeutics Limited (CHM.AX).
Where is Chimeric Therapeutics Limited headquartered?
Chimeric Therapeutics Limited is headquartered in Australia.
Does CHM.AX pay a dividend?
Chimeric Therapeutics Limited (CHM.AX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did CHM.AX go public?
Chimeric Therapeutics Limited (CHM.AX) completed its initial public offering in 2021.